Second major study from COSMOS finds that participants randomized to receive a daily multivitamin supplement showed improvements in memory compared to placebo.
The study, COSMOS-Web, involved over 3,500 participants aged 60 and older who took either multivitamins or a placebo and underwent annual cognitive assessments for three years. The multivitamin group demonstrated significant memory improvement equivalent to a 3.1 year reversal of cognitive aging compared to the placebo group, with the greatest benefits observed in participants with a history of cardiovascular disease. These findings corroborate those from another COSMOS study, COSMOS-Mind, which associated daily multivitamin supplementation with a 60% slowing of global cognitive aging.
Randomized clinical trials have shown few effective strategies to improve memory or slow cognitive decline among older adults. Nutritional interventions may play an important role because the brain requires several nutrients for optimal health, and deficiencies in one or more of these nutrients may accelerate cognitive decline. The COcoa Supplement and Multivitamin Outcomes Study (COSMOS), a large-scale nationwide randomized trial directed by researchers at Brigham and Women’s Hospital (BWH), a founding member of Mass General Brigham, included two separate clinical trials (COSMOS-Web and COSMOS-Mind) testing multivitamin supplementation on changes in cognitive function.
In a study published on May 24 in The American Journal of Clinical Nutrition, researchers from the Brigham and their collaborators at Columbia University report from COSMOS-Web that daily multivitamin supplements, compared to placebo, improved memory among participants. The study is the second from COSMOS, along with the previously published COSMOS-Mind, to find an improvement in memory function among those taking a multivitamin.
“The findings that a daily multivitamin improved memory and slowed cognitive decline in two separate studies in the COSMOS randomized trial is remarkable, suggesting that multivitamin supplementation holds promise as a safe, accessible, and affordable approach to protecting cognitive health in older adults,” said co-author JoAnn Manson, MD, chief of the Brigham’s Division of Preventive Medicine. Manson is a co-leader of the parent COSMOS trial with Howard Sesso, ScD, associate director of the Brigham’s Division of Preventive Medicine.
Sesso adds, “With these two studies on cognition in hand for COSMOS, and more to come in COSMOS, it is critical to understand how a daily multivitamin may protect against memory loss and cognitive decline, and whether particular subgroups based on nutritional status or other factors may benefit more, or less.”
The newly published COSMOS-Web trial included more than 3,500 participants aged 60 and older who completed novel web-based assessments of memory and cognition annually over 3 years. Compared to the placebo group, participants randomized to multivitamin supplementation did significantly better on the memory tests at the prespecified primary time point of 1 year, with benefits sustained across the 3 years of follow-up. The researchers estimated that the multivitamin intervention improved memory performance by the equivalent of 3.1 years compared to the placebo group. Intriguingly, both COSMOS cognitive studies also showed that the participants who benefitted the most may be those with a history of cardiovascular disease.
“Because of our innovative approach of assessing cognitive outcomes using internet-based tests, we were able to examine the effects of a multivitamin in thousands of study participants. The findings are promising and certainly set the stage for important follow-up studies about the impact of multivitamin supplementation on cognition,” said Adam Brickman, PhD, who co-led the COSMOS-Web study with Lok-Kin Yeung, PhD, at Columbia University. “Most older adults are worried about memory changes that occur with aging. Our study suggests that supplementation with multivitamins may be a simple and inexpensive way for older adults to slow down memory loss,” added Yeung.
Results from COSMOS-Web, conducted as a collaboration between the Brigham and Columbia University, provide confirmation of earlier findings from COSMOS-Mind linking daily multivitamins to slowing of cognitive decline. COSMOS-Mind, which was conducted as a collaboration between the Brigham and Wake Forest School of Medicine, had tested 2,200 older adults for 3 years and showed that randomized assignment to a daily multivitamin supplement was associated with a 60% slowing of global cognitive aging compared to placebo, equivalent to 1.8 years reduction in cognitive decline (study was funded by the National Institute on Aging and published in Alzheimer’s and Dementia in September 2022).
The authors note that the COSMOS-Web study provides evidence that multivitamin supplementation has cognitive benefits but further research will be necessary to identify the specific nutrients contributing the most to this benefit and the underlying mechanisms involved. Additional research is also needed to determine whether the findings are generalizable to a more diverse study population with lower educational levels and lower socioeconomic status.
For more on this research, see Major Study Finds Daily Multivitamin Improves Memory in Older Adults.
Reference: “Multivitamin supplementation improves memory in older adults: A randomized clinical trial” by Lok-Kin Yeung, Daniel M. Alschuler, Melanie Wall, Heike Luttmann-Gibson, Trisha Copeland, Christiane Hale, Richard P. Sloan, Howard D. Sesso, JoAnn E. Manson and Adam M. Brickman, 24 May 2023, American Journal of Clinical Nutrition.
Authors: Lok-Kin Yeung (Columbia), Daniel M. Alschuler (New York State Psychiatric Institute), Melanie Wall (Columbia), Heike Luttman-Gibson (Brigham and Women’s Hospital/Harvard), Trisha Copeland (Brigham and Women’s/Harvard), Richard P. Sloan (Columbia), Howard D. Sesso (Brigham and Women’s/Harvard), JoAnn E. Manson (Brigham and Women’s/Harvard) and Adam M. Brickman (Columbia).
Disclosures: Sesso additionally reported receiving investigator-initiated grants from Pure Encapsulations and Pfizer Inc. and honoraria and/or travel for lectures from the Council for Responsible Nutrition, BASF, NIH, and the American Society of Nutrition during the conduct of the study.
Funding: COSMOS-Web was supported by investigator-initiated grants from Mars Edge, a segment of Mars Inc. and the National Institutes of Health (AG050657, AG071611, EY025623, and HL157665). Multivitamin and placebo tablets and packaging were donated by Pfizer, Inc Consumer Healthcare (now Haleon).